104 related articles for article (PubMed ID: 38841024)
1. The Development of IgE Multiple Myeloma Following Treatment for Locally Advanced Prostate Cancer.
Fujita M; Suzuki I; Mizuno T; Kobayashi H; Kambara T
Cureus; 2024 May; 16(5):e59732. PubMed ID: 38841024
[TBL] [Abstract][Full Text] [Related]
2. [Multiple myeloma diagnosed during hormonal therapy for prostate cancer: report of two cases].
Yoshinaga A; Okada Y; Ichiyanagi N; Kamata S
Hinyokika Kiyo; 2012 May; 58(5):243-7. PubMed ID: 22767278
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Early-onset multiple myeloma: an illustrative case report.
Kaufman R
J Manipulative Physiol Ther; 2007 Sep; 30(7):543-9. PubMed ID: 17870425
[TBL] [Abstract][Full Text] [Related]
5. IgE multiple myeloma: detection and follow-up.
Nafría Jiménez B; Oliveros Conejero R
Adv Lab Med; 2022 Mar; 3(1):79-90. PubMed ID: 37359442
[TBL] [Abstract][Full Text] [Related]
6. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.
Daniels-Wells TR; Helguera G; Leuchter RK; Quintero R; Kozman M; Rodríguez JA; Ortiz-Sánchez E; Martínez-Maza O; Schultes BC; Nicodemus CF; Penichet ML
BMC Cancer; 2013 Apr; 13():195. PubMed ID: 23594731
[TBL] [Abstract][Full Text] [Related]
7. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Common complaints, difficult diagnosis: multiple myeloma.
Dvorak C
J Am Acad Nurse Pract; 2006 May; 18(5):190-4. PubMed ID: 16681705
[TBL] [Abstract][Full Text] [Related]
10. Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer.
Ke Z; Xu Y; Shu Y; Wang C; Wu B; Zhang B; Xiang P; Hu X
Transl Cancer Res; 2024 Feb; 13(2):676-685. PubMed ID: 38482405
[TBL] [Abstract][Full Text] [Related]
11. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.
King MT; Chen MH; Collette L; Neven A; Bolla M; D'Amico AV
JAMA Netw Open; 2021 May; 4(5):e2111092. PubMed ID: 33999161
[TBL] [Abstract][Full Text] [Related]
12. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of prostate-specific antigen in patients with locally advanced prostate cancer treated with high energy neutron beam therapy: preliminary results.
Saroja KR; Oesterling JE; Hendrickson F; Cohen L; Mansell J
Urology; 1993 Jun; 41(6):540-7. PubMed ID: 7685957
[TBL] [Abstract][Full Text] [Related]
15. A Challenging Diagnosis Of Rare Co-Existent Multiple Myeloma And Prostate Adenocarcinoma: A Systematic Review Of Case Reports.
Iqbal R; Rehman S; Sukaina M; Ullah H; Hameed M; Chattha U
J Pak Med Assoc; 2023 Aug; 73(8):1684-1692. PubMed ID: 37697762
[TBL] [Abstract][Full Text] [Related]
16. Multimodal therapy including robot-assisted radical cystoprostatectomy for locally advanced prostate cancer with bladder and ureteral invasion: A case report.
Okumi M; Kujime Y; Matsumura S; Kitakaze H; Nakano K; Hongo S; Yoshioka I; Takada S
IJU Case Rep; 2022 Sep; 5(5):402-405. PubMed ID: 36090930
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
18. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
[TBL] [Abstract][Full Text] [Related]
19. Chest pain without a clue-ultrasound to rescue occult multiple myeloma: A case report.
Chawla G; Dutt N; Deokar K; Meena VK
World J Radiol; 2019 Dec; 11(12):144-148. PubMed ID: 31885830
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
